Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy does not increase cardiovascular risk
In plain terms: Is testosterone therapy safe for your heart?
Part of: 💊 Testosterone therapy (TRT)
Mostly reassuring, not fully settled. The big 2023 TRAVERSE trial found no increase in major cardiac events (heart attack, stroke, cardiac death) — putting an old scare to rest — but it did find more atrial fibrillation and blood clots in the lungs. So: probably safe for major events in the right patients, with a real, unresolved signal for irregular heartbeat and clots.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
TRT's **cardiovascular safety** is reassuring on the biggest question but **not fully settled**. The large TRAVERSE randomized trial (2023) found testosterone was **non-inferior to placebo for major cardiac events** (heart attack, stroke, CV death) — strong evidence against the earlier scare — and several meta-analyses agree. BUT TRAVERSE also flagged **more atrial fibrillation and pulmonary embol
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Garcia-Becerra CA et al. 2026 · Int J Impot Res | meta-analysis | supports | high | Meta 41 RCTs (n=11,161): TTh not associated with increased MACE (OR 0.83, 95% CI 0.52-1.32, ns) - supports short-to-mid-term cardiovascular safety (authors note long-term data still needed). |
| Lincoff AM et al. 2023 · N Engl J Med | RCT | mixed | high | TRAVERSE (n=5246): non-inferior to placebo for MACE (HR 0.96) BUT higher atrial fibrillation, acute kidney injury, and pulmonary embolism in TRT group. |
| Xu L et al. 2013 · BMC Med | meta-analysis | contradicts | moderate | Meta 27 RCTs: increased CV-event risk overall (OR 1.54); non-industry trials OR 2.06 vs industry OR 0.89. |
| Basaria S et al. 2012 · J Androl | RCT | contradicts | moderate | TOM trial substudy: trial halted early for excess CV events; greater free-T rise associated with events. |
| Vigen R et al. 2013 · JAMA | observational | contradicts | moderate | Retrospective cohort (n=8709): TT associated with increased death/MI/stroke (25.7% vs 19.9% at 3y). |
| Alexander GC et al. 2017 · Am J Med | meta-analysis | mixed | low | SR/meta 39 RCTs + 10 observational: no significant increase in MI/stroke/mortality, but evidence rated very low quality. |
| Cannarella R et al. 2023 · J Clin Med | meta-analysis | supports | moderate | Meta (14 RCTs + observational): no increased arterial/venous thrombosis, stroke, MI, or mortality in RCTs. |
| Ayele HT et al. 2021 · Drug Saf | meta-analysis | mixed | moderate | Meta 13 RCTs (n=5050): TRT not associated with VTE (RR 1.03) but wide CIs cannot rule out risk. |
| Finkle WD et al. 2014 · PLoS One | observational | contradicts | moderate | Self-controlled cohort (n=55,593): post-prescription MI rate ratio 1.36 overall; 2.19 in men >=65. |
| Glueck CJ et al. 2017 · Clin Appl Thromb Hemost | observational | mixed | low | Case-control: VTE peaks ~3 months post-initiation, concentrated in men with underlying thrombophilia (unmasks Factor V Leiden/high Lp(a)). |
| Sood A et al. 2023 · J Urol | meta-analysis | supports | high | Meta 26 RCTs (n=10,941): no significant differences in all-cause/CV mortality, MI, stroke, CHF, AF, PE, or VTE. |
| Haddad RM et al. 2007 · Mayo Clin Proc | meta-analysis | tested-null | moderate | Meta 30 RCTs: any-CV-event OR 1.82 (95% CI 0.78-4.23, ns); weakly reassuring. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.